Ruben A. Mesa, MD | Authors


Follow-Up Results for Ruxolitinib in the Second-Line Treatment of PV

December 12, 2017

Ruben A. Mesa, MD, Director of the UT Health San Antonio Cancer Center, discusses 4-year follow-up results from the phase III RESPONSE trial, which investigated ruxolitinib (Jafaki) with best available therapy for the treatment of polycythemia vera (PV) during the 2017 ASH Annual Meeting.

Evolving NCCN Guidelines for MPNs

November 10, 2016

Ruben A. Mesa, MD, chair, Division of Hematology and Medical Oncology, deputy director, professor of Medicine, Mayo Clinic, discusses the NCCN Clinical Practice Guidelines for myeloproliferative neoplasms (MPNs) and who the recommendations will transition over the next year. Mesa spoke on the topic during an interview at the 34th Annual Chemotherapy Foundation Symposium™, held November 9-11, 2016 in New York City.